Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma

Albert Moghrabi, Herb Fuchs, Mark Brown, S. Clifford Schold, Michael Graham, Joanne Kurtzberg, Robert Tien, Gary Felsberg, Daniel H. Lachance, O. Michael Colvin, Dagmar Oette, Gary J. Allegretta, Beverly Hockenberger, Elizabeth Stewart, Lee Ferrell, Tracy Kerby, Margaret Duncan‐Brown, Darell D. Bigner, Henry S. Friedman

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Thirteen patients with recurrent medulloblastoma were treated with cyclophosphamide in association with Sargramostim. Cyclophosphamide was given at doses ranging between 1.0–2.5 g/m2 daily for two doses. Sargramostim was given at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the ANC was more than 1,000 cells/μl for two consecutive days. A total of 33 courses were given with toxicity consisting of grade 4 neutropenia in all courses and grade 3–4 thrombocytopenia in 10 of 13 patients. There were no deaths related to infection or bleeding. Four patients were taken off study because of prolonged myelosuppression. Three of these patients were at the 2.5 g/m2 level, and of these three, two developed lung toxicity (grades 2 and 4, respectively). One patient developed an allergic reaction following the first injection of Sargramostim and was also taken off study. Of 10 evaluable patients, there were 9 PR and 1 SD. We conclude that cyclophosphamide at a dose of 2.0 g/m2/day × 2 days q 4 weeks in association with Sargramostim demonstrates marked activity with acceptable toxicity in patients with recurrent medulloblastoma. © 1995 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)190-196
Number of pages7
JournalMedical and Pediatric Oncology
Volume25
Issue number3
DOIs
StatePublished - Sep 1995

Keywords

  • Sargramostim
  • cyclophosphamide
  • recurrent medulloblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma'. Together they form a unique fingerprint.

  • Cite this

    Moghrabi, A., Fuchs, H., Brown, M., Schold, S. C., Graham, M., Kurtzberg, J., Tien, R., Felsberg, G., Lachance, D. H., Colvin, O. M., Oette, D., Allegretta, G. J., Hockenberger, B., Stewart, E., Ferrell, L., Kerby, T., Duncan‐Brown, M., Bigner, D. D., & Friedman, H. S. (1995). Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. Medical and Pediatric Oncology, 25(3), 190-196. https://doi.org/10.1002/mpo.2950250306